318 results on '"Kumada, Hiromitsu"'
Search Results
2. Impact of genetic polymorphism on personalized diet and exercise program for steatotic liver disease.
3. Impact of genetic polymorphism to personalized diet and exercise program for steatotic liver disease
4. Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study
5. Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors
6. Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan
7. Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma
8. Efficacy and safety of telaprevir with natural human interferon‐β and ribavirin in Japanese chronic hepatitis C patients with depression
9. Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride
10. Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs
11. Potential of a no‐touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas
12. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double‐blind trial
13. Renal safety and biochemical changes for two years of tenofovir alafenamide after switching from long‐term other nucleotide analogues treatment in patients with chronic hepatitis B
14. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b
15. Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis
16. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
17. Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan
18. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
19. Potential impact of joint association of alanine aminotransferase and gamma-glutamyltransferase on insulin resistance in Japan: The Toranomon Hospital Health Management Center Study 19 (TOPICS 19)
20. Potential of a no-touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study
21. Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers
22. Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients
23. Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan
24. Clinical significance of hepatectomy for primary biliary cirrhosis patients with hepatocellular carcinoma: Report of a single center case series and review of the published work
25. Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance
26. Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir
27. Minimum resection margin should be based on tumor size in hepatectomy for hepatocellular carcinoma in hepatoviral infection patients
28. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease
29. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
30. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma
31. Magnetic resonance laparoscopy: A new non-invasive technique for the assessment of chronic viral liver disease
32. Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma
33. Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients
34. Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B
35. Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis
36. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load
37. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B.
38. Efficacy of reduction therapy of natural human β-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load
39. Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL
40. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients
41. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B
42. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively
43. Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis
44. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy
45. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus
46. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009
47. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C
48. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer
49. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C
50. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.